A detailed history of Zions Bancorporation, N.A. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Zions Bancorporation, N.A. holds 592 shares of ALNY stock, worth $144,974. This represents 0.01% of its overall portfolio holdings.

Number of Shares
592
Previous 20 2860.0%
Holding current value
$144,974
Previous $4,000 3950.0%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$233.81 - $287.01 $133,739 - $164,169
572 Added 2860.0%
592 $162,000
Q2 2024

Aug 08, 2024

BUY
$143.31 - $247.0 $859 - $1,482
6 Added 42.86%
20 $4,000
Q1 2024

May 14, 2024

SELL
$146.51 - $198.2 $732 - $991
-5 Reduced 26.32%
14 $2,000
Q4 2023

Feb 12, 2024

SELL
$151.41 - $196.57 $757 - $982
-5 Reduced 20.83%
19 $3,000
Q2 2023

Jul 28, 2023

BUY
$185.01 - $212.05 $1,850 - $2,120
10 Added 71.43%
24 $4,000
Q1 2023

May 10, 2023

SELL
$182.66 - $235.53 $1,278 - $1,648
-7 Reduced 33.33%
14 $2,000
Q4 2022

Feb 10, 2023

SELL
$185.53 - $241.31 $185 - $241
-1 Reduced 4.55%
21 $4,000
Q3 2022

Nov 08, 2022

BUY
$138.54 - $232.0 $415 - $696
3 Added 15.79%
22 $4,000
Q2 2022

Aug 05, 2022

BUY
$120.42 - $169.29 $2,287 - $3,216
19 New
19 $3,000
Q1 2021

May 13, 2021

SELL
$126.83 - $175.69 $4,058 - $5,622
-32 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$70.9 - $87.82 $2,268 - $2,810
32 New
32 $3,000
Q2 2019

Jul 09, 2019

SELL
$65.86 - $92.79 $2,963 - $4,175
-45 Closed
0 $0
Q1 2019

May 10, 2019

BUY
$72.76 - $93.45 $2,328 - $2,990
32 Added 246.15%
45 $4,000
Q4 2018

Feb 13, 2019

BUY
$62.67 - $88.33 $814 - $1,148
13 New
13 $1,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Zions Bancorporation, N.A. Portfolio

Follow Zions Bancorporation, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zions Bancorporation, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Zions Bancorporation, N.A. with notifications on news.